Skip Navigation

Schizophrenia Bulletin 2003 29(1):45-55;
© 2003 by Oxford University Press and the Maryland Psychiatric Research Center (MPRC)
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Keefe, R. S.E.
Right arrow Articles by Sano, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Keefe, R. S.E.
Right arrow Articles by Sano, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press

Neurocognitive Assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project Schizophrenia Trial: Development, Methodology, and Rationale

Richard S.E. Keefe, Ph.D., Richard C. Mohs, Ph.D., Robert M. Bilder, Ph.D., Philip D. Harvey, Ph.D., Michael F. Green, Ph.D., Herbert Y. Meltzer, M.D., James M. Gold, Ph.D. and Mary Sano, Ph.D.
Director, Neurocognitive Assessment Unit, Clinical Antipsychotic Trials of Intervention Effectiveness project; and Associate Professor of Psychiatry and Behavioral Sciences, Duke University Medical Center Durham, NC
Lilly Research Fellow, Eli Lilly and Company, Indianapolis, IN
Chief of Medical Psychology-Neuropsychology, Neuropsychiatric Institute and Hospital, Geffen School of Medicine, University of California Los Angeles
Professor of Psychiatry, Mt. Sinai School of Medicine
Professor in Residence, Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, CA
Bixler Professor of Psychiatry, Vanderbilt University School of Medicine Nashville, TN
Associate Professor of Psychiatry, Maryland Psychiatric Research Center, University of Maryland School of Medicine Baltimore, MD
Professor, Department of Psychiatry, Mount Sinai School of Medicine, Bronx Veterans Medical Research Center Bronx, NY

Send reprint requests to Dr. R. Keefe, Box 3270, Duke University Medical Center, Durham, NC 27710; e-mail: rsekeefe{at}acpub.duke.edu

Patients with schizophrenia are severely impaired in crucial aspects of neurocognitive function. This impairment is the strongest clinical correlate of poor long-term outcome and adaptive dysfunction. Reports of neurocognitive enhancement with second generation antipsychotic medications have thus offered promise for improvement in the long-term outcome of patients with schizophrenia. However, the majority of these studies have had serious weaknesses in methodology, such as open-label design, small samples, or inappropriate dosing of medications. More recent studies have addressed these methodological issues but have been of short duration and have largely been sponsored by pharmaceutical companies. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project is a unique opportunity to address the comparative neurocognitive effectiveness of available antipsychotic medications. This article describes the neurocognitive methods used in the schizophrenia trial of the CATIE project, including the selection and training of neurocognitive raters, patient inclusion criteria for assessment, rationale for the choice of neurocognitive instruments, and methodology for each neurocognitive test.

Keywords: Neurocognitive function / cognition / antipsychotic medications / neuropsychology / schizophrenia / clinical trials


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Schizophr BullHome page
S. Mohamed, R. Rosenheck, J. McEvoy, M. Swartz, S. Stroup, and J. A. Lieberman
Cross-sectional and Longitudinal Relationships Between Insight and Attitudes Toward Medication and Clinical Outcomes in Chronic Schizophrenia
Schizophr Bull, March 1, 2009; 35(2): 336 - 346.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
S. Mohamed, R. Rosenheck, M. Swartz, S. Stroup, J. A. Lieberman, and R. S.E. Keefe
Relationship of Cognition and Psychopathology to Functional Impairment in Schizophrenia
Am J Psychiatry, August 1, 2008; 165(8): 978 - 987.
[Abstract] [Full Text] [PDF]

Home page
 Psychiatr. Serv.Home page
M. S. Swartz, T. S. Stroup, J. P. McEvoy, S. M. Davis, R. A. Rosenheck, R. S. E. Keefe, J. K. Hsiao, and J. A. Lieberman
What CATIE Found: Results From the Schizophrenia Trial
Psychiatr Serv, May 1, 2008; 59(5): 500 - 506.
[Abstract] [Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
R. S. E. Keefe, R. M. Bilder, S. M. Davis, P. D. Harvey, B. W. Palmer, J. M. Gold, H. Y. Meltzer, M. F. Green, G. Capuano, T. S. Stroup, et al.
Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial
Arch Gen Psychiatry, June 1, 2007; 64(6): 633 - 647.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
T. S. Stroup, J. A. Lieberman, J. P. McEvoy, M. S. Swartz, S. M. Davis, G. A. Capuano, R. A. Rosenheck, R. S.E. Keefe, A. L. Miller, I. Belz, et al.
Effectiveness of Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia After Discontinuing Perphenazine: A CATIE Study
Am J Psychiatry, March 1, 2007; 164(3): 415 - 427.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
M. S. Swartz, D. O. Perkins, T. S. Stroup, S. M. Davis, G. Capuano, R. A. Rosenheck, F. Reimherr, M. F. McGee, R. S.E. Keefe, J. P. McEvoy, et al.
Effects of Antipsychotic Medications on Psychosocial Functioning in Patients With Chronic Schizophrenia: Findings From the NIMH CATIE Study
Am J Psychiatry, March 1, 2007; 164(3): 428 - 436.
[Abstract] [Full Text] [PDF]

Home page
 FocusHome page
T. S. Stroup, J. A. Lieberman, J. P. McEvoy, M. S. Swartz, S. M. Davis, R. A. Rosenheck, D. O. Perkins, R. S.E. Keefe, C. E. Davis, J. Severe, et al.
Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic
Focus, September 1, 2006; 4(4): 539.
[Full Text] [PDF]

Home page
 Psychiatr. Serv.Home page
M. H. Chakos, I. D. Glick, A. L. Miller, M. B. Hamner, D. D. Miller, J. K. Patel, A. Tapp, R. S. E. Keefe, and R. A. Rosenheck
Baseline Use of Concomitant Psychotropic Medications to Treat Schizophrenia in the CATIE Trial
Psychiatr Serv, August 1, 2006; 57(8): 1094 - 1101.
[Abstract] [Full Text] [PDF]

Home page
 Psychiatr. Serv.Home page
L. A. Chwastiak, R. A. Rosenheck, J. P. McEvoy, R. S. Keefe, M. S. Swartz, and J. A. Lieberman
Interrelationships of Psychiatric Symptom Severity, Medical Comorbidity, and Functioning in Schizophrenia
Psychiatr Serv, August 1, 2006; 57(8): 1102 - 1109.
[Abstract] [Full Text] [PDF]

Home page
 Psychiatr. Serv.Home page
D. A. Perlick, R. A. Rosenheck, R. Kaczynski, M. S. Swartz, J. M. Canive, and J. A. Lieberman
Components and Correlates of Family Burden in Schizophrenia
Psychiatr Serv, August 1, 2006; 57(8): 1117 - 1125.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
T. S. Stroup, J. A. Lieberman, J. P. McEvoy, M. S. Swartz, S. M. Davis, R. A. Rosenheck, D. O. Perkins, R. S.E. Keefe, C. E. Davis, J. Severe, et al.
Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic
Am J Psychiatry, April 1, 2006; 163(4): 611 - 622.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
R. Rosenheck, D. Leslie, R. Keefe, J. McEvoy, M. Swartz, D. Perkins, S. Stroup, J. K. Hsiao, J. Lieberman, and CATIE Study Investigators Group
Barriers to Employment for People With Schizophrenia
Am J Psychiatry, March 1, 2006; 163(3): 411 - 417.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. PsychiatryHome page
R. Rosenheck, S. Stroup, R. S. E. Keefe, J. McEvoy, M. Swartz, D. Perkins, J. Hsiao, M. Shumway, and J. Lieberman
Measuring outcome priorities and preferences in people with schizophrenia
The British Journal of Psychiatry, December 1, 2005; 187(6): 529 - 536.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. A. Lieberman, T. S. Stroup, J. P. McEvoy, M. S. Swartz, R. A. Rosenheck, D. O. Perkins, R. S.E. Keefe, S. M. Davis, C. E. Davis, B. D. Lebowitz, et al.
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
N. Engl. J. Med., September 22, 2005; 353(12): 1209 - 1223.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.